This is a prospective, observational cohort study to evaluate the clinical impact of novel Monoclonal AntiBodies (MAB) in B-cell Non-Hodgkin Lymphoma (NHL) in Italian clinical practice.
Patients with diagnosis of B-cell NHL and need of treatment (as per guideline indications), both first-line and relapsed or refractory.
Patients aimed to be treated in indication with a "novel" MAB (alone or in combination) based on presence of an EMA clinical indication since 2020 and prescribed according to the indications for use authorized for marketing in Italy.
Signed written informed consent.
Being involved in a prospective interventional trial outside indication.
648-approved indication.
5% AIFA support.
Compassionate use.
Fondazione Italiana Linfomi - ETS
Lead sponsor
Roche Pharma AG
Collaborator